FilingReader Intelligence

Rossari Biotech reports 11% revenue growth in Q1

July 20, 2025 at 08:09 AM UTCBy FilingReader AI

Rossari Biotech reported Q1 FY26 consolidated revenues of INR 543.7 crore, an 11% increase year-over-year. EBITDA rose 4.6% to INR 67.9 crore, with PAT at INR 33.6 crore.

Standalone revenue grew 21.6% to INR 365.8 crore, with EBITDA up 10.3% to INR 43.9 crore. The HPPC and AHN divisions achieved growth of 16% and 12% respectively.

Capacity expansion projects are progressing, with commissioning scheduled over the coming quarters, expected to drive growth from FY27 onwards.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

BSE:ROSSARIBombay Stock Exchange

News Alerts

Get instant email alerts when ROSSARI BIOTECH publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →